Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut Bergonié
Fred Hutchinson Cancer Center
Indiana University
Bayer
UNC Lineberger Comprehensive Cancer Center
Institut National de la Santé Et de la Recherche Médicale, France
PharmaMar
Institut Bergonié
Esperas Pharma Inc.
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Sarcoma Oncology Research Center, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Stanford University
Cyteir Therapeutics, Inc.
BeiGene
Taproot Health
National Cancer Institute (NCI)
University Hospital, Antwerp
TopAlliance Biosciences
Mundipharma Research Limited
Emory University
Xencor, Inc.
Gene Surgery LLC
Cedars-Sinai Medical Center
TransThera Sciences (Nanjing), Inc.
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Corvus Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
University Hospital, Strasbourg, France
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
Children's Oncology Group
Emory University
Tempest Therapeutics
Prelude Therapeutics
Case Comprehensive Cancer Center
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Istituto Clinico Humanitas
Roswell Park Cancer Institute
Novartis